I’d happily buy this 5.5% yield in an ISA and hold it for 10 years

I think you could see strong returns from this top income share, says Royston Wild.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Of the many brilliant big-yielding shares that UK investors can buy today, Vistry Group (LSE: VTY) is one that I’d happily load up on right now.

It remains to be seen whether the ‘Boris Bounce’ that has boosted property transactions since mid-December will last given ongoing Brexit uncertainty. Regardless, I reckon the housebuilders like Vistry should continue to make progress in 2020 and beyond.

Formerly known as Bovis Homes, trading at the FTSE 250 firm remained strong throughout the last year. The positive contribution of cheap loans and the government’s Help To Buy purchase scheme helped the company post record profits last year. 

Business has been so strong, in fact, that Vistry said profits would sail past market expectations. It witnessed what it described as a “significant step up” in average weekly sales rates, to 0.58 from 0.5 in 2018. But of course, it’s not the only housebuilder to have released blockbuster trading numbers in recent weeks.

Building things up

It’s no wonder that these construction colossi are making big plans to turbocharge production rates. Indeed, latest industry data underlined the strength of appetite for Vistry and its peers to capitalise on this fertile environment.

According to the National House Building Council (NHBC), some 161,022 homes were registered to be built in Britain in 2019. This was up 1% from the previous year and was the highest level since 2007. The news is significant because NHBC new home registrations account for four-fifths of all homes created in the UK.

Vistry certainly has plans to light a fire under build rates in the short-to-medium term. The acquisition of Linden Homes from Galliford Try, completed at the turn of the year, gives it the capacity to build a whopping 12,000 homes per year.

Another top trader

Latest trading numbers just released from Vistry’s FTSE 250 peer Redrow illustrate the strength of the market too. While its total order book was flat at around £1.2bn as of December, the value of its private net reservations on its books soared 18% year-on-year to £936m.

Moreover, it said that trading has been “resilient” in the first five weeks of 2020. The value of its reservations rose 15% at £180m, it added.

Stunning value, big dividends

Given recent news flow, it’s understandable that City brokers remain quite upbeat over the robustness of the industry. It also explains why they have been upgrading their forecasts over recent weeks again. Expectations that 2020 earnings will rise by mid-single-digit percentages at the tail end of last year have given way to predictions that profits will boom 23% this year.

Improved sentiment towards Vistry has shoved its share price 17% higher in the past month alone. And the high chance of more upgrades to broker estimates means that more gains could be in the offing. Combine this with a cheap forward P/E ratio of 10.6 times and smashing 5.5% dividend yield and I reckon the business is a top buy right now.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Redrow. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

£10,000 invested in Micron stock six months ago is now worth…

Dr James Fox talks about Micron stock -- one of his best investments over the past six months. Does he…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

100%+ earnings growth and a P/E of 8.5? Could this be a once-in-a-decade stock market gift for value investors?

As the UK stock market makes a go at a recovery, Mark Hartley identifies one FTSE 250 stock that could…

Read more »

Investing Articles

Greggs shares are up 90% in a decade. What could the next decade bring?

Mark Hartley remains optimistic about his Greggs shares, citing long-term growth. But could they still offer an opportunity for value…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

5 steps towards a Stocks & Shares ISA worth £1m

Millions of Britons are missing out on wealth creation because they're not following these steps. Dr James Fox details how…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Is now a good time to start investing in the wealth-building stock market?

The stock market is a battle-hardened builder of wealth long term. But with risks mounting, is now a good time…

Read more »

Investing Articles

£10,000 invested in red-hot Tesco shares just 1 week ago is now worth…

Harvey Jones is impressed by how well Tesco shares have defied recent stock market volatility. So can this FTSE 100…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

See the income from investing a £20k ISA in this UK stock before it goes ex-dividend on 9 April

Harvey Jones says this UK stock offers one of the highest yields on the FTSE 100. Investors need to act…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

What’s going on with the AstraZeneca share price now?

Dr James Fox explores the recent movements in the AstraZeneca share price and evaluates whether it's still a good long-term…

Read more »